Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

The recent use of prostate-specific membrane antigen as a biological target have improved
the theragnostic approach to prostate and other types of cancer. Radiopharmaceuticals …

Ac-225 has lately drawn considerable attention as a radioisotope for targeted alpha therapy
treatment for certain types of prostate, blood-derived, and disseminated cancers, but its …

Alpha particle-emitting radiopharmaceuticals are in high demand for use in targeted alpha
therapy. Ac-225 is currently produced using Th-229, but its annual production remains low …

Objective The aim of this study was to evaluate the radiation dosimetry of alpha-emitter 225
Ac-DOTA-rituximab using Monte Carlo simulation of 64 Cu-DOTA-rituximab. Methods CD20 …

Abstract Targeted Alpha Therapy is a therapy method that can be applied to late-stage
cancers, including bone metastases, and it is a hope for millions of people. This study is an …

A newer therapy for the treatment of bone metastases due to castration-resistant prostate
cancer (mCRPC) is the administration of 223 Ra-dichloride (223 RaCl 2) or 177 Lu-iPSMA …

Relative biological effectiveness is a radiobiological parameter relevant in radiotherapy
planning and useful in evaluating the physiological impact of radiation in different tissues …

Objectives. The aim of this work is to evaluate energy deposition in the nucleus and
cytoplasm in targeted alpha therapy of metastatic castration-resistant prostate cancer by …